Literature DB >> 23773295

Attenuated psychosis syndrome in DSM-5.

Ming T Tsuang1, Jim Van Os, Rajiv Tandon, Deanna M Barch, Juan Bustillo, Wolfgang Gaebel, Raquel E Gur, Stephan Heckers, Dolores Malaspina, Michael J Owen, Susan Schultz, William Carpenter.   

Abstract

Despite advances in the treatment of schizophrenia over the past half-century, the illness is frequently associated with a poor outcome. This is principally related to the late identification and intervention in the course of the illness by which time patients have experienced a substantial amount of socio-occupational decline that can be difficult to reverse. The emphasis has therefore shifted to defining psychosis-risk syndromes and evaluating treatments that can prevent transition to psychosis in these ultra-high risk groups. To consider the appropriateness of adding psychosis risk syndrome to our diagnostic nomenclature, the psychotic disorders work group extensively reviewed all available data, consulted a range of experts, and carefully considered the variety of expert and public comments on the topic. It was clear that reliable methods were available to define a syndrome characterized by sub-threshold psychotic symptoms (in severity or duration) and which was associated with a very significant increase in the risk of development of a full-fledged psychotic disorder (schizophrenia spectrum, psychotic mood disorder, and other psychotic disorders) within the next year. At the same time, the majority of individuals with "attenuated psychotic symptoms" had one or more other current psychiatric comorbid conditions (usually mood or anxiety disorders, substance use disorder; Fusar-Poli 2012) and exhibited a range of psychiatric outcomes other than conversion to psychosis (significant proportions either fully recover or develop some other psychiatric disorder, with a minority developing a psychotic disorder). Although the reliability of the diagnosis is well established in academic and research settings, it was found to be less so in community and other clinical settings. Furthermore, the nosological relationship of attenuated psychosis syndrome (APS) to schizotypal personality disorder and other psychiatric conditions was unclear. Further study will hopefully resolve these questions. The work group decided to recommend the inclusion of attenuated psychosis syndrome as a category in the appendix (Section 3) of DSM-5 as a condition for further study.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Attenuated psychosis syndrome; High risk; Intervention; Prodromes; Schizophrenia

Mesh:

Year:  2013        PMID: 23773295      PMCID: PMC3778120          DOI: 10.1016/j.schres.2013.05.004

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  40 in total

Review 1.  Ultra high-risk state for psychosis and non-transition: a systematic review.

Authors:  Andor E Simon; Eva Velthorst; Dorien H Nieman; Don Linszen; Daniel Umbricht; Lieuwe de Haan
Journal:  Schizophr Res       Date:  2011-07-23       Impact factor: 4.939

2.  Nosological status and definition of schizophrenia: Some considerations for DSM-V and ICD-11.

Authors:  Rajiv Tandon; Mario Maj
Journal:  Asian J Psychiatr       Date:  2008-11-25

3.  Redeeming diagnosis in psychiatry: timing versus specificity.

Authors:  Patrick McGorry; Jim van Os
Journal:  Lancet       Date:  2013-01-26       Impact factor: 79.321

Review 4.  The psychosis high-risk state: a comprehensive state-of-the-art review.

Authors:  Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

5.  Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies.

Authors:  Paolo Fusar-Poli; Joaquim Radua; Philip McGuire; Stefan Borgwardt
Journal:  Schizophr Bull       Date:  2011-11-10       Impact factor: 9.306

6.  Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis.

Authors:  P Fusar-Poli; J M Stone; M R Broome; I Valli; A Mechelli; M A McLean; D J Lythgoe; R L O'Gorman; G J Barker; P K McGuire
Journal:  Arch Gen Psychiatry       Date:  2011-05-02

7.  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Authors:  G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger
Journal:  Arch Gen Psychiatry       Date:  2010-02

8.  Early traumatic experiences in those at clinical high risk for psychosis.

Authors:  Jean Addington; Jacqueline Stowkowy; Kristin S Cadenhead; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Tyrone D Cannon
Journal:  Early Interv Psychiatry       Date:  2013-01-24       Impact factor: 2.732

9.  Attenuated psychosis and the schizophrenia prodrome: current status of risk identification and psychosis prevention.

Authors:  Neeraj Tandon; Jai Shah; Matcheri S Keshavan; Rajiv Tandon
Journal:  Neuropsychiatry (London)       Date:  2012

10.  Anticipating DSM-V: should psychosis risk become a diagnostic class?

Authors:  William T Carpenter
Journal:  Schizophr Bull       Date:  2009-07-24       Impact factor: 9.306

View more
  40 in total

1.  Attenuated Mismatch Negativity in Attenuated Psychosis Syndrome Predicts Psychosis: Can Galantamine-Memantine Combination Prevent Psychosis?

Authors:  Maju Mathew Koola
Journal:  Mol Neuropsychiatry       Date:  2018-06-07

Review 2.  Cognition and brain function in schizotypy: a selective review.

Authors:  Ulrich Ettinger; Christine Mohr; Diane C Gooding; Alex S Cohen; Alexander Rapp; Corinna Haenschel; Sohee Park
Journal:  Schizophr Bull       Date:  2015-03       Impact factor: 9.306

3.  Early intervention: how early and with what?

Authors:  William T Carpenter; Robert W Buchanan
Journal:  Schizophr Bull       Date:  2014-11-14       Impact factor: 9.306

4.  Baseline demographics, clinical features and predictors of conversion among 200 individuals in a longitudinal prospective psychosis-risk cohort.

Authors:  G Brucato; M D Masucci; L Y Arndt; S Ben-David; T Colibazzi; C M Corcoran; A H Crumbley; F M Crump; K E Gill; D Kimhy; A Lister; S A Schobel; L H Yang; J A Lieberman; R R Girgis
Journal:  Psychol Med       Date:  2017-03-02       Impact factor: 7.723

Review 5.  Is prevention a realistic goal for schizophrenia?

Authors:  Christian Kohler; Karin E Borgmann-Winter; Irene Hurford; Eli Neustadter; James Yi; Monica E Calkins
Journal:  Curr Psychiatry Rep       Date:  2014-04       Impact factor: 5.285

6.  Whither the psychosis-neurosis borderline.

Authors:  Ian Kelleher; Mary Cannon
Journal:  Schizophr Bull       Date:  2014-01-16       Impact factor: 9.306

7.  Conceptualizing psychotic disorders: don't throw the baby out with the bathwater.

Authors:  Rajiv Tandon
Journal:  World Psychiatry       Date:  2016-06       Impact factor: 49.548

8.  Schizotypal personality disorder in individuals with the Attenuated Psychosis Syndrome: Frequent co-occurrence without an increased risk for conversion to threshold psychosis.

Authors:  Anthony W Zoghbi; Joel A Bernanke; Julia Gleichman; Michael D Masucci; Cheryl M Corcoran; Allegra Califano; Justin Segovia; Tiziano Colibazzi; Michael B First; Gary Brucato; Ragy R Girgis
Journal:  J Psychiatr Res       Date:  2019-04-21       Impact factor: 4.791

9.  North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms.

Authors:  Jean Addington; Lu Liu; Lisa Buchy; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Daniel H Mathalon; Thomas H McGlashan
Journal:  J Nerv Ment Dis       Date:  2015-05       Impact factor: 2.254

10.  Neurodevelopmental Genomic Strategies in the Study of the Psychosis Spectrum.

Authors:  Raquel E Gur
Journal:  Nebr Symp Motiv       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.